Disclaimer. This site reads publicly available research papers and corporate filings and explains what they say. It is not investment advice and does not recommend buying or selling any security. Historical cases shown here are computed from public data; the sample sizes are small and are not a basis for prediction. We do not answer questions about individual stocks.
Readouts · Company page
Yunovia
Company facts
- Status
- Unlisted
- Founded
- 2023-11-01
- CEO
- 서진식, 최성구
- Headquarters
- 경기도 화성시 삼성1로1길 20 (석우동)
- Industry
- KSIC 73909
- Fiscal year end
- 12
- Source
- DART
Readouts that mention this company
National R&D projects (NTIS)
1
item
50,000,000
Cumulative government R&D funding (KRW)
Largest projects
- A6-001 fusion 모핵 기반 ANO6 억제제 선도물질 최적화 2023 · 보건복지부
Korean patent filings (KIPRIS)
30
item
Recently published patents
- 신규한 리모실락토바실러스 루테리 ID-D01 및 이를 포함하는 조성물 20250729
- CFTR 조절제의 결정형 및 이의 제조방법 20250428
- 난용성 약물 및 고분자를 포함하는 무정형 고체 분산체 조성물 20250414
- 치환된 융합 이미다졸 유도체의 제조 방법 20250328
- 오토탁신 억제제 화합물의 신규한 결정형 20241015
Papers with affiliated authors (OpenAlex)
No records
Companies in the same readouts
- Dong-A ST
- Chugai Pharmaceutical
- Eli Lilly
- Hangzhou Zhongmei Huadong
- Jiangsu Hengrui
- Eccogene
- Novo Nordisk
- Hanmi Pharmaceutical
Last updated 2026-09-21